616 related articles for article (PubMed ID: 31196874)
21. Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort.
Rahman A; Jairath V; Feagan BG; Khanna R; Shariff SZ; Allen BN; Jenkyn KB; Vinden C; Jeyarajah J; Mosli M; Benchimol E
Aliment Pharmacol Ther; 2019 Nov; 50(10):1086-1093. PubMed ID: 31621934
[TBL] [Abstract][Full Text] [Related]
22. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
23. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
[TBL] [Abstract][Full Text] [Related]
24. Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Abraham B; Eksteen B; Nedd K; Kale H; Patel D; Stephens J; Shelbaya A; Chambers R; Soonasra A
Adv Ther; 2022 May; 39(5):2109-2127. PubMed ID: 35296993
[TBL] [Abstract][Full Text] [Related]
25. The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.
Severs M; Oldenburg B; van Bodegraven AA; Siersema PD; Mangen MJ;
J Crohns Colitis; 2017 Mar; 11(3):289-296. PubMed ID: 27571772
[TBL] [Abstract][Full Text] [Related]
26. International variation in medication prescription rates among elderly patients with inflammatory bowel disease.
Benchimol EI; Cook SF; Erichsen R; Long MD; Bernstein CN; Wong J; Carroll CF; Frøslev T; Sampson T; Kappelman MD
J Crohns Colitis; 2013 Dec; 7(11):878-89. PubMed ID: 23018106
[TBL] [Abstract][Full Text] [Related]
27. Real-World Treatment Patterns and Healthcare Resource Use for Ulcerative Colitis and Crohn's Disease in Italy.
Dovizio M; Hartz S; Buzzoni C; Redondo I; Nedeljkovic Protic M; Birra D; Perrone V; Veronesi C; Degli Esposti L; Armuzzi A
Adv Ther; 2024 Jun; 41(6):2282-2298. PubMed ID: 38619721
[TBL] [Abstract][Full Text] [Related]
28. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004.
Nguyen GC; Tuskey A; Dassopoulos T; Harris ML; Brant SR
Inflamm Bowel Dis; 2007 Dec; 13(12):1529-35. PubMed ID: 17828784
[TBL] [Abstract][Full Text] [Related]
29. Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.
Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
Aliment Pharmacol Ther; 2017 Apr; 45(8):1043-1057. PubMed ID: 28239873
[TBL] [Abstract][Full Text] [Related]
30. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Jung YS; Han M; Park S; Cheon JH
Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
[TBL] [Abstract][Full Text] [Related]
31. Rates of Intestinal Resection and Colectomy in Inflammatory Bowel Disease Patients After Initiation of Biologics: A Cohort Study.
Khoudari G; Mansoor E; Click B; Alkhayyat M; Saleh MA; Sinh P; Katz J; Cooper GS; Regueiro M
Clin Gastroenterol Hepatol; 2022 May; 20(5):e974-e983. PubMed ID: 33065311
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway.
Zhao M; Lirhus S; Lördal M; Langholz E; Knudsen T; Voutilainen M; Høivik ML; Moum B; Anisdahl K; Saebø B; Haiko P; Malmgren C; Coskun M; Melberg HO; Burisch J
Aliment Pharmacol Ther; 2022 Sep; 56(6):989-1006. PubMed ID: 35902223
[TBL] [Abstract][Full Text] [Related]
33. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
34. Exploring treatment of inflammatory bowel disease with infliximab in the Middle East and Northern Africa: An analysis of the HARIR observational cohort study.
Alharbi O; Hamed W; Salem O; Taylor C; Besar A; Sharaf M
Saudi J Gastroenterol; 2023; 29(3):164-170. PubMed ID: 37313946
[TBL] [Abstract][Full Text] [Related]
35. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.
van der Valk ME; Mangen MJ; Leenders M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk CJ; Vermeijden JR; Siersema PD; van Oijen MG; Oldenburg B;
Gut; 2014 Jan; 63(1):72-9. PubMed ID: 23135759
[TBL] [Abstract][Full Text] [Related]
36. Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.
Guasch M; Cañete F; Ordás I; Iglesias-Flores E; Clos A; Gisbert JP; Taxonera C; Vera I; Mínguez M; Guardiola J; Rivero M; Nos P; Gomollón F; Barrio J; de Francisco R; López-Sanromán A; Martín-Arranz MD; Garcia-Planella E; Camargo R; García-López S; de Castro L; Calvet X; Esteve M; Mañosa M; Domènech E;
J Gastroenterol Hepatol; 2020 Dec; 35(12):2080-2087. PubMed ID: 32350906
[TBL] [Abstract][Full Text] [Related]
37. No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015.
Verdon C; Reinglas J; Coulombe J; Gonczi L; Bessissow T; Afif W; Vutcovici M; Wild G; Seidman EG; Bitton A; Brassard P; Lakatos PL
Inflamm Bowel Dis; 2021 Apr; 27(5):655-661. PubMed ID: 32676662
[TBL] [Abstract][Full Text] [Related]
38. A four-decade analysis of the incidence trends, sociodemographic and clinical characteristics of inflammatory bowel disease patients at single tertiary centre, Kuala Lumpur, Malaysia.
Mokhtar NM; Nawawi KNM; Verasingam J; Zhiqin W; Sagap I; Azman ZAM; Mazlan L; Hamid HA; Yaacob NY; Rose IM; Den ELN; Wan MS; Raja Ali RA
BMC Public Health; 2019 Jun; 19(Suppl 4):550. PubMed ID: 31196184
[TBL] [Abstract][Full Text] [Related]
39. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
40. Changes in surgery rates among hospitalized patients with inflammatory bowel disease in Japan from 2015 to 2019: A nationwide administrative database analysis.
Yoshida S; Imai S; Fushimi K
J Gastroenterol Hepatol; 2024 Feb; 39(2):272-279. PubMed ID: 37961024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
